Patient Preferences for Lung Cancer Treatment: A Qualitative Study Protocol Among Advanced Lung Cancer Patients

Frontiers in Public Health

Meredith Y. Smith¹  Ilaria Durosini²  Luca Bailo²  Dario Monzani³  Gabriella Pravettoni³  Reinhard Arnou⁴  Isabelle Huys⁴  Rosanne Janssens⁴  Kristiaan Nackaerts⁵  Marie Vandevelde⁵  Evelyne Louis⁵  Eva G. Katz⁶  Ian Smith⁷  G. Ardine de Wit⁷  Jorien Veldwijk⁸  Giulia Galli⁹  Marina Garassino⁹ 

[1] Alexion Pharmaceuticals, Inc., University of Southern California School of Pharmacy, Los Angeles, CA, United States;Applied Research Division for Cognitive and Psychological Science, IEO, European Institute of Oncology IRCCS, Milan, Italy;Applied Research Division for Cognitive and Psychological Science, IEO, European Institute of Oncology IRCCS, Milan, Italy;Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy;Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium;Department of Pneumology/Respiratory Oncology, University Hospital Leuven, KU Leuven, Leuven, Belgium;Janssen Research and Development, Raritan, NJ, United States;Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands;School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, Netherlands;Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands;Unit of Thoracic Oncology, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy;

关键词: patient preferences;    drug decision-making;    lung cancer;    drug development;    patient-centered research;    patient involvement;    focus group discussion;    nominal group technique;   

DOI  :  10.3389/fpubh.2021.622154

来源: Frontiers

【 授权许可】

CC BY